The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients

[1] Oshiro C(2009)Taxane pathway Pharmacogenet Genomics 19 979-983

[2] Marsh S(2008)Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer Clin Cancer Res 14 3312-3318

[3] McLeod H(2002)C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141 K protein and low-level drug resistance Mol Cancer Ther 1 611-616

[4] Hamada A(2004)Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8) Pharmacogenetics 14 441-452

[5] Sissung T(2003)Increased transcriptional activity of the CYP3A4*1B promoter variant Environ Mol Mutagen 42 299-305

[6] Price DK(2001)Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 383-391

[7] Imai Y(2000)Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 3473-3478

[8] Nakane M(2001)The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells Pharmacogenetics 11 293-298

[9] Kage K(2007)Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients Eur J Clin Pharmacol 63 1161-1169

[10] Letschert K(2005)An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore Drug Metab Rev 37 327-378

[1] Oshiro C(2009)Taxane pathway Pharmacogenet Genomics 19 979-983

[2] Marsh S(2008)Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer Clin Cancer Res 14 3312-3318

[3] McLeod H(2002)C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141 K protein and low-level drug resistance Mol Cancer Ther 1 611-616

[4] Hamada A(2004)Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8) Pharmacogenetics 14 441-452

[5] Sissung T(2003)Increased transcriptional activity of the CYP3A4*1B promoter variant Environ Mol Mutagen 42 299-305

[6] Price DK(2001)Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 383-391

[7] Imai Y(2000)Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 3473-3478

[8] Nakane M(2001)The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells Pharmacogenetics 11 293-298

[9] Kage K(2007)Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients Eur J Clin Pharmacol 63 1161-1169

[10] Letschert K(2005)An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore Drug Metab Rev 37 327-378